Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.33 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24757308 | 1.00 | BACE1 (0.38) | BACE1BACE2AKR1C3AKR1C2LMNA | |
| SCHEMBL24758209 | 0.95 | BACE1 (0.39) | BACE1BACE2AKR1C3AKR1C2LMNA | |
| SCHEMBL30107009 | 0.95 | BACE1 (0.39) | BACE1BACE2AKR1C3AKR1C2LMNA | |
| SCHEMBL30107028 | 0.89 | NR3C1 (0.38) | BACE1BACE2AKR1C3AKR1C2NR3C1 | |
| SCHEMBL24758290 | 0.89 | NR3C1 (0.38) | BACE1BACE2AKR1C3AKR1C2NR3C1 | |
| SCHEMBL24759005 | 0.87 | SCN10A (0.43) | AKR1C3AKR1C2 | |
| SCHEMBL24906467 | 0.87 | SCN10A (0.43) | AKR1C3AKR1C2 | |
| SCHEMBL30107019 | 0.85 | NR3C1 (0.39) | BACE1BACE2AKR1C3AKR1C2LMNA | |
| SCHEMBL24758387 | 0.85 | NR3C1 (0.39) | BACE1BACE2AKR1C3AKR1C2LMNA | |
| SCHEMBL24759014 | 0.85 | NR3C1 (0.40) | BACE1AKR1C3AKR1C2NR3C1SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | BACE1 2182/4885BACE2 2797/4885AKR1C3 1950/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | BACE1 2182/4885BACE2 2797/4885AKR1C3 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.